Two Months and Out: The CEO Exit That Has Biotech Investors Nervous

Their lead candidate, HLP003, is a deuterated version of psilocin (the active compound in magic mushrooms) currently in Phase 3 trials for major depressive disorder. The FDA gave it Breakthrough Therapy Designation, which is essentially the agency saying, "This looks promising enough that we'll fast-track it." Topline data from the APPROACH trial is expected in Q4 2026.

Behind that sits HLP004, a deuterated DMT being tested in Phase 2 for generalized anxiety disorder. Enrollment is complete, with data expected soon. The company also holds more than 350 patents, over 100 of which have been granted, extending protection through 2041.

This isn't a one-compound startup. Helus has a real pipeline, real intellectual property, and a real shot at bringing novel mental health treatments to market. Which makes the CEO revolving door even more puzzling.

The Hiring Spree That Makes This Weirder

If you're looking for signs of a company in crisis, Helus sends mixed signals. In the weeks before Cola's exit, the company was aggressively building out its leadership team:

• February 24: Dr. Freda Lewis-Hall, former Chief Medical Officer of Pfizer, joined the board and became Chair of the Scientific Advisory Committee.
• March 12: Jill Conwell was appointed Chief People Officer.
• April 16: Dr. Ken Kramer, a neuroscience veteran with over 20 years of experience whose most recent role was at Bristol Myers Squibb, came on as SVP of Medical Affairs.

That's not a company winding down. That's a company gearing up. You don't recruit a former Pfizer CMO to your advisory board if you're planning to fold. But you also don't fire your CEO after two months if everything is going according to plan.

The most generous interpretation: the board realized quickly that Cola wasn't the right cultural or strategic fit for what's ahead, and they acted decisively. The less generous interpretation: something is messy behind the scenes, and investors are being kept in the dark.

Why Wall Street Should Pay Attention

Helus stock was already under pressure before this. Shares traded around $5.77 after the announcement, down approximately 26% year-to-date and sitting roughly 41% below the 52-week high.

Rapid CEO turnover at a clinical-stage biotech is like a restaurant changing head chefs two months after a grand reopening. Maybe the food will still be great. But you'd be forgiven for canceling your reservation.

For investors, the math is straightforward. Helus has Phase 3 data coming in Q4. That's the most important catalyst on the calendar, and it's arriving while the company operates under interim leadership. Clinical trials don't pause because the C-suite is in flux, but execution risk just went up. Recruitment, regulatory strategy, and investor communication all depend on stable leadership, and right now, Helus is asking people to trust a placeholder.

The Bigger Pattern

Helus isn't the only biotech dealing with leadership whiplash. Across the industry, boards have become quicker to pull the trigger on CEO changes. Novo Nordisk replaced its longtime chief in mid-2025 after a guidance cut. AbbVie transitioned leadership in 2024 as Humira's patent protection eroded.

But those were billion-dollar companies with deep management benches. For a clinical-stage biotech with a market cap measured in the hundreds of millions, losing a CEO after two months carries disproportionate weight. Every month of leadership uncertainty is a month closer to a data readout that will define the company's future.

What Comes Next

Eric So knows the company better than anyone; he co-founded it. His two decades of experience in corporate strategy and finance make him a reasonable caretaker. But interim CEOs are, by definition, temporary. The board needs to find someone permanent, and they need to do it before Q4 data arrives.

The real question isn't just who comes next. It's whether the board can explain what happened with Cola. Investors, analysts, and potential hires are all watching. Silence might feel safe in the short term, but it breeds the one thing clinical-stage biotechs can't afford: doubt.

Helus has the science. It has the pipeline. It has the FDA's attention. What it doesn't have, at least not right now, is a story that inspires confidence in the people running the show. And in biotech, the people matter almost as much as the molecules.